-
1 Comment
Biofrontera AG is currently in a long term downtrend where the price is trading 2.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.3.
Biofrontera AG's total revenue sank by 8.6% to $5M since the same quarter in the previous year.
Its net income has increased by 53.5% to $-5M since the same quarter in the previous year.
Based on the above factors, Biofrontera AG gets an overall score of 2/5.
| Industry | Drug Manufacturers - Specialty & Generic |
|---|---|
| Exchange | F |
| CurrencyCode | EUR |
| ISIN | DE0006046113 |
| Sector | Healthcare |
| PE Ratio | None |
|---|---|
| Target Price | 5.55 |
| Beta | 0.64 |
| Market Cap | 984K |
| Dividend Yield | None |
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; and Belixos, a medical skin care series for irritated and sensitive skin. It has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for B8F.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
